NHWK
NightHawk Biosciences Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
heat biologics is a clinical-stage company focused on developing its proprietary impact™ (immune pan-antigen cytotoxic therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers. heat's impact therapy is a first-in-class, fully human immunotherapy that functions as both an immune stimulator and an antigen-delivery system. impact effectively transforms living allogeneic cells into "osmotic pumps" that continuously secrete cancerous antigens to robustly stimulate the immune system against the targeted cancer. impact therapy is applicable to a wide range of cancers. heat is currently conducting two phase 2 clinical trials with its hs-110 to treat non-small cell lung cancer (nsclc) and its hs-410 to treat bladder cancer.
Market Cap: 9.65 Million
Primary Exchange: NYSE MKT LLC
Website: http://www.heatbio.com/
Shares Outstanding: 26.1 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.5793875533071869
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 463 trading days
From: 2022-07-12 To: 2024-02-05
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|